Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31062Editorial articleПередовая статьяReview ArticleCURRENT TRENDS IN CLASSIFICATION AND TREATMENT OF SYSTEMIC VASCULITIS ASSOCIATED WITH ANTI-NEUTROPHILIC CYTOPLASMIC ANTIBODIES: RESULTS OF 2011СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О КЛАССИФИКАЦИИ И ЛЕЧЕНИИ СИСТЕМНЫХ ВАСКУЛИТОВ, АССОЦИИРОВАННЫХ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ: ИТОГИ 2011 гBeketovaT VБекетоваТатьяна Валентиновна

канд. мед. наук, ст. науч. сотр НИИР РАМН

TVBEK@rambler.ruNasonovE LНасоновЕвгений Львович

д-р мед. наук, проф., акад. РАМН, дир. НИИ ревматологии РАМН

sokrat@irramn.ruResearch Institute of RheumatologyФедеральное Государственное бюджетное учреждение Научноисследовательский институт ревматологии РАМНResearch Institute of RheumatologyФГБУ "Научно-исследовательский институт ревматологии" РАМН15052012845NO5 (2012)ТОМ 84, №5 (2012)687410042020Copyright ©; 2012, Consilium MedicumCopyright ©; 2012, ООО "Консилиум Медикум"2012Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31062

Systemic vasculitis (SV) pathogenetically associated with anti-neutrophilic cytoplasmic antibodies (ANCA) is the subject of intensive research in present-day rheumatology. There were noticeable changes in ANCA-associated SV (ANCA-SV) nomenclature in 2011 as well as mid-term success was achieved in the study of biological anti-B-cell therapy in this disease. European recommendations on rituximab administration in ANCA-SV have been developed. Russian Register of ANCA-SV patients on rituximab treatment is presented. State-of-the art in ANCA-SV research is reviewed.

Системные васкулиты (СВ), патогенетически связанные с антинейтрофильными цитоплазматическими антителами (АНЦА), в настоящее время являются одной из наиболее динамично развивающихся областей ревматологии. За 2011 г. произошли существенные изменения, касающиеся номенклатуры СВ, ассоциированных с АНЦА (АНЦА-СВ), пройден важный рубеж в изучении биологической анти-В-клеточной терапии при этих заболеваниях и разработаны Европейские рекомендации по применению ритуксимаба (РТМ) при АНЦА-СВ; в нашей стране создан регистр больных АНЦА-СВ, получающих РТМ. В статье обобщены основные итоги оценки состояния этой проблемы на современном этапе.

anti-neutrophilic cytoplasmic antibodiessystemic vasculitisclassificationtreatmentантинейтрофильные цитоплазматические антителасистемные васкулитыклассификациялечениеLie J. T. Nomenclature and classification of vasculitis: plus cachange, plus c’est la meme chose. Arthr. and Rheum. 1994; 37: 181—186.Van der Woude F. J., Rasmussen N., Lobatto S. et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985; 1: 425—429.Jennette J. C., Falk R. J., Andrassy K. et al. Nomenclature of systemicvasculitides. Proposal of an international consensus conference. Arthr. and Rheum. 1994; 37: 187—192.Watts R.A., Suppiah R., Merkel P. A., Luqmani R. Systemic vasculitis — is it time to reclassify? Rheumatology 2011; 50: 643—645.Basu N., Watts R., Bajema I. et al. EULAR points to consider in thedevelopment of classification and diagnostic criteria in systemic vasculitis. Ann. Rheum. Dis. 2010; 69: 1744—1750.Luqmani R. A., Suppiah R., Grayson P. C. et al. Nomenclature and classification of vasculitis — update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS). Clin. Exp. Immunol. 2011; 164 (Suppl. 1): 11—13.Falk R., Gross W., Guillevin L. et al. Granulomatosis with polyangiitis ( Wegener’s): an alternative name for Wegener’s granulomatosis. Arthr. and Rheum. 2011; 63: 863—864.Woywodt A., Haubitz M., Haller H., Matteson E. L. Wegener’s granulomatosis. Lancet 2006; 367: 1362—1366.Klinger H. Grenzformen der Periarteriitis nodosa. Frankfurt. Z. Pathol. 1931; 42: 455—480.Rössle R. Zum Formenkreis der rheumatischen Gewebsveranderungen mit besonderer Berucksichtigung der rheumatischen Gefassentzundungen. Virchows Arch. 1933; 288: 780—832.Wegener F. Uber generalisierte, septische Gefasserkrankungen. Verhandl Dtsch. Gesellsch. Pathol. 1936; 29: 202—210.Wegener F. Uber eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr. Pathol. Anat. Allg. Pathol. 1939; 102: 36—63.Wegener F. Ueber eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. About a peculiar rhinogenic granulomatosis with marked involvement of the arterial system and kidneys. Beitr. Pathol. Anat. 1939; 102: 30—68.Jennette J. C. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener’s granulomatosis). Clin. Exp. Immunol. 2011; 164 (Suppl. 1): 7—10.Mark E. J., Matsubara O., Tan-Liu N. S., Fienberg R. The pulmonary biopsy in the early diagnosis of Wegener’s (pathergic) granulomatosis: a study based on 35 open lung biopsies. Hum. Pathol. 1988; 19: 1065—1071.Falk R. J., Gross W. L., Guillevin L. et al. Granulomatosis with polyangiitis (Wegener?s): an alternative name for Wegener’s granulomatosis. A joint proposal of the American College of Rheumatology, the American Society of Nephrology, and the European League against Rheumatism. Arthr. and Rheum. 2011: 63 (4); 863—864.Falk R. J., Gross W. L., Guillevin L. et al. Granulomatosis with Polyangiitis (Wegener’s): An Alternative Name for Wegener’s Granulomatosis. J. Am. Soc. Nephrol. 2011; 22 (4): 587.Novack S. N., Pearson C. M. Cyclophosphamide therapy in Wegener’s granulomatosis. N. Engl. J. Med. 1971; 284: 938—942.Fauci A. S., Wolff S. M. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973; 52: 535—561.Zhu L. P., Cupps T. R., Whalen G. et al. Selective effects of cyclophosphamide therapy on activation, proliferation and differentiation of human B cells. J. Clin. Invest. 1987; 79: 1082—1090.Tervaert J. W., Huitema M. G., Hene R. J. et al. Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709—711.Bosch X., Guilabert А., Espinosa G. et al. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis. J. A. M. A. 2007; 298: 655—669.Specks U., Fervenza F. C., McDonald T. J., Hogan M.C. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthr. and Rheum. 2001; 44: 2836—2840.Stone J., Merkel P., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363: 221—232.Jones R. B., Cohen Tervaert J. W., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363: 211—220.Cohen Tervaert J.W. Rituximab in ANCA-associated vasculitis: a revolution? Nephrol. Dial. Transplant. 2011; 26 (10): 3077—3079.Guerry M.-J. C. J., Brogan P., Bruce I. N. et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2011;50:doi:10.1093/rheumatology/ ker150.Popa E. R., Stegeman C. A., Bos N. A. et al. Differential Band T-cell activation in Wegener’s granulomatosis. J. Allergy Clin. Immunol. 1999; 103: 885—894.van de Veerdonk F. L., Lauwerys B., Marijnissen R. J. et al. The anti— CD20 antibody rituximab reduces the Th17 cell response. Arthr. and Rheum. 2011; 63: 1507—1516 doi: 10.1002/art.30314.Wilde B., Thewissen M., van Paassen P. et al. Patients with ANCA associated vasculitis in long-term remission have increased numbers of circulating IL-10 producing Th17 cells. Clin. Exp. Immunol. 2011; 164: 152.Lamprecht P., Gross W. L., Kabelitz D. et al. T cell alterations and lymphoid neogenesis favoring autoimmunity in Wegener’s granulomatosis. Arthr. and Rheum. 2007; 56: 1725—1727.Jones R. B., Walsh M., Jayne D. R. W. et al. Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin. Exp. Immunol. 2011; 164: 57.Specks U., Stone J. H. For the RAVE-ITN Research Group. Longterm efficacy and safety results of the RAVE trial. Clin. Exp. Immunol. 2011; 164: 65.Guillevin L., Mahr А. New horizons for treatment of ANCA-associated vasculitides. Time to oust cyclophosphamide and opt for rituximab? Rheumatology 2011; doi:10.1093/rheumatology/ker187.van Oers M. H., van Glabbeke M., Giurgea L. et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J. Clin. Oncol. 2010; 28: 2853—2858.Tarella C., Passera R., Magni M. et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J. Clin. Oncol. 2011; 29: 814— 824.Mansfield N., Hamour S., Marie-Habib A. et al. Prolonged disease-free remission following Rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol. Dial. Transplant. 2011; 26 (10): 3280—3286.Kartin-Seba R., Goldbin J., Keoch K. A. et al. Rituximab for em-mission, induction and maintenance in ANCA-associated vasculitis: a single centered 10-year experience in 108 patients. Arthr. and Rheum. 2010; 62 (Suppl 10): 680.Roubaud-Baudron C., Pagnoux C., Meaux-Ruault N. et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J. Rheumatol. 2012; 39: 1; doi:10/3899/ jrheum.110143.Jones R. B., Smith R., Guerry M. J. et al. Protocolized versus non-protocolized RTX treatment for refractory ANCA-AAV. Clin. Exp. Immunol. 2011; 164: 58.Niles J., McGrath M., Laliberte K. Continuous RTX therapy for AN-CA-AAV. Clin. Exp. Immunol. 2011; 164: 62.